Zacks Investment Research
10 Dec 2025, 14:36 UTC · 41w ago
Verdict
Headline takes no side. We score PAHC +1.00 across three claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Phibro Animal Health (PAHC) reported 81% growth in medicated feed additives (MFA) revenues for the first quarter of fiscal 2026.
So whatSignificant top-line growth in a core business segment typically drives positive valuation adjustments for the specific equity.
More positive than 92% of claims this week
Phibro Animal Health shares have increased 59.6% year-to-date, significantly outperforming the S&P 500's 14.6% gain.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 63% of claims this week
Phibro has expanded its production capacity by beginning operations at a new vaccine production facility in Guarulhos, Brazil.
More positive than 50% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The company has surged 59.6% this year, holds a Zacks Rank #1 (Strong Buy), and reports strong revenue growth in its MFA business.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
−10.9%
Price is moving against the score
$34.10 vs $38.28 close before publication (Dec 9) · not market-adjusted
PAHC chart →
